Literature DB >> 10857802

The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group.

A D Moore1, M A Petri, S Manzi, D A Isenberg, C Gordon, J L Senécal, Y St Pierre, L Joseph, J Penrod, P R Fortin, N Sutcliffe, J R Goulet, D Choquette, T Grodzicky, J M Esdaile, A E Clarke.   

Abstract

OBJECTIVE: As part of an ongoing study of health resource utilization and diminished productivity in patients with systemic lupus erythematosus (SLE), the use of alternative medical therapies was assessed.
METHODS: A cohort of 707 patients with SLE from 3 countries completed questionnaires on demographics, social support, health status (using the Short Form 36 health survey), satisfaction with health care, health resource utilization (conventional resources and alternative therapies), and time losses in labor market and non-labor market activities. Annual direct and indirect costs (1997 Canadian dollars) were calculated and compared for users and nonusers of alternative medical therapies.
RESULTS: Among the 707 patients, 352 (49.8%) were found to use alternative therapies and at similar rates across Canada, the United States, and the United Kingdom. Users were younger and better educated than nonusers, exhibited poorer levels of self-rated health status and satisfaction with medical care, and had minimal to no objective evidence of worse disease (according to the revised Systemic Lupus Activity Measure instrument). The mean of log direct medical costs for conventional resources was higher for users of select alternative therapies compared with nonusers. In a logistic regression, neither the number of alternative therapies used nor the individual therapy increased the probability of incurring indirect costs.
CONCLUSION: The use of alternative medical therapies is common in patients with SLE. Users of many alternative medical therapies accrue greater conventional medical costs compared with nonusers. The use of alternative medical therapy may be a marker for care-seeking behavior associated with higher consumption of conventional medical resources in the absence of demonstrable additional morbidity and should be considered in future cost analyses of patients with SLE.

Entities:  

Mesh:

Year:  2000        PMID: 10857802     DOI: 10.1002/1529-0131(200006)43:6<1410::AID-ANR27>3.0.CO;2-U

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

Review 1.  Treatment of lupus: impact on quality of life.

Authors:  Sergio M A Toloza; Winston Sequeira; Meenakshi Jolly
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

2.  Integrated medicine in the management of chronic illness: a qualitative study.

Authors:  Sarah B Brien; Felicity L Bishop; Kirsty Riggs; David Stevenson; Victoria Freire; George Lewith
Journal:  Br J Gen Pract       Date:  2011-02       Impact factor: 5.386

Review 3.  Non-pharmacologic therapies for systemic lupus erythematosus.

Authors:  M Fangtham; S Kasturi; R R Bannuru; J L Nash; C Wang
Journal:  Lupus       Date:  2019-04-08       Impact factor: 2.911

Review 4.  n-3 polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis.

Authors:  James J Pestka
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-03-01       Impact factor: 4.006

Review 5.  Updated review of complementary and alternative medicine treatments for systemic lupus erythematosus.

Authors:  Carol M Greco; Claire Nakajima; Susan Manzi
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

6.  Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study.

Authors:  Simon M Chatfield; Shyamali C Dharmage; Anthony Boers; Belinda J Martin; Russell R C Buchanan; Walter P Maksymowych; Lionel Schachna
Journal:  Clin Rheumatol       Date:  2008-11-05       Impact factor: 2.980

Review 7.  Prevalence of use of complementary and alternative medicine (CAM) by patients/consumers in the UK: systematic review of surveys.

Authors:  Paul Posadzki; Leala K Watson; Amani Alotaibi; Edzard Ernst
Journal:  Clin Med (Lond)       Date:  2013-04       Impact factor: 2.659

8.  Association of complementary or alternative medicine use with quality of life, functional status or cumulated damage in chronic rheumatic diseases.

Authors:  José Alvarez-Nemegyei; Alberta Bautista-Botello; Jorge Dávila-Velázquez
Journal:  Clin Rheumatol       Date:  2009-01-13       Impact factor: 2.980

9.  Acupuncture for systemic lupus erythematosus: a pilot RCT feasibility and safety study.

Authors:  C M Greco; A H Kao; K Maksimowicz-McKinnon; R M Glick; M Houze; S M Sereika; J Balk; S Manzi
Journal:  Lupus       Date:  2008-12       Impact factor: 2.911

10.  Complementary and alternative medicine use by osteoporosis clinic patients.

Authors:  C A K Y Chong; N Diaz-Granados; G A Hawker; S Jamal; R G Josse; A M Cheung
Journal:  Osteoporos Int       Date:  2007-06-30       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.